Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes
Journal of Diabetes and Clinical Research · 2024
DOI: 10.33696/diabetes.6.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes and Clinical Research, 2024. Verfasst von Nasser Mikhail und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Herzinsuffizienz, Diabetes mellitus
Abstract (Originalsprache)
The glucagon-like peptide 1 receptor (GLP-1R) agonist semaglutide is effective for the treatment of obesity and type 2 diabetes mellitus (T2DM). The purpose of this article is to define the therapeutic role of semaglutide for obesity-related heart failure with preserved ejection fraction (HF-pEF). Methods: Critical review of 2 recent randomized trials, the Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) and STEP-HFpEF DM. The latter 2 studies had similar design and endpoints that evaluated efficacy and safety of semaglutide 2.4 mg/w in obese subjects without and with T2DM, respectively. The 2 primary endpoints were the change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) and the percentage change in body weight. After 52 weeks, placebo-corrected amelioration in the KCCQ-CSS was similar in subjects without and with diabetes, 7.8 points (95% CI, 4.8 to 10.9; P
Zitieren
APA
Mikhail, N., & Wali, S. (2024). Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes. Journal of Diabetes and Clinical Research. https://doi.org/10.33696/diabetes.6.059
Vancouver
Mikhail N, Wali S. Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes. Journal of Diabetes and Clinical Research. 2024. doi:10.33696/diabetes.6.059
BibTeX
@article{Mikhail2024,
author = {Mikhail, Nasser and Wali, Soma},
title = {Semaglutide for Treatment of Obesity-Related Heart Failure with Preserved Ejection Fraction in Patients with and without Diabetes},
journal = {Journal of Diabetes and Clinical Research},
year = {2024},
doi = {10.33696/diabetes.6.059}
}
EUVIMED